Life sciences firm OptiBiotix Health PLC (LON:OPTI) is to launch products containing its cholesterol reducing strain (LPLDL) at the Vitafoods Europe Trade Show.
The trade show, which is being held in Geneva on 9-11 May, provides opportunities to connect with 16,500 industry decision makers from the supplements, “nutraceutical”, functional food and beverage industries.
Aim-listed OptioBiotix will be launching the first of its range of heart health products, including CholBiome, which as the name suggests targets cholesterol levels, and CardioBiome, which aims to ease a number of conditions that lead to cardiovascular disease.
The product launches will further increase industry awareness of OptiBiotix's proprietary cholesterol reducing strain, and are the first of a number of heart health formulations being licensed to manufacturing and formulation partners for distribution and sale into the European market.
Discussions are progressing with corporate partners for the manufacture and distribution of products containing LPLDL in the US, Asian and other international markets, OptiBiotix said.
“OptiBiotix has made significant progress in developing, protecting, testing and raising industry awareness of its LPLDL cholesterol and blood pressure reducing strain," said Stephen O'Hara, chief executive of OptiBiotix.
“This has created a high level of interest in commercialising LPLDL both as a raw ingredient and as a component in higher value branded products. This creates the potential to generate revenues for different formulations and presentations across numerous territories at multiple points in the value chain with a mixture of national and international partners.” he added.